%0 Clinical Trial Protocol
%T Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial.
%A Verburg A
%A Bor WL
%A Küçük IT
%A Henriques JPS
%A Vink MA
%A Ruifrok WT
%A Plomp J
%A Heestermans TACM
%A Schotborgh CE
%A Vlaar PJ
%A Magro M
%A Rikken SAOF
%A van den Broek WWA
%A van Mieghem CAG
%A Cornelis K
%A Rosseel L
%A Dujardin KS
%A Vandeloo B
%A Vandendriessche T
%A Ferdinande B
%A van 't Hof AWJ
%A Tijssen JGP
%A Limbruno U
%A De Caterina R
%A Rubboli A
%A Angiolillo DJ
%A Adriaenssens T
%A Dewilde W
%A Ten Berg JM
%J EuroIntervention
%V 20
%N 14
%D 2024 Jul 15
%M 39007830
%F 7.728
%R 10.4244/EIJ-D-24-00100
%X The optimal antithrombotic management of atrial fibrillation (AF) patients who require oral anticoagulation (OAC) undergoing percutaneous coronary intervention (PCI) remains unclear. Current guidelines recommend dual antithrombotic therapy (DAT; OAC plus P2Y12 inhibitor - preferably clopidogrel) after a short course of triple antithrombotic therapy (TAT; DAT plus aspirin). Although DAT reduces bleeding risk compared to TAT, this is counterbalanced by an increase in ischaemic events. Aspirin provides early ischaemic benefit, but TAT is associated with an increased haemorrhagic burden; therefore, we propose a 30-day dual antiplatelet therapy (DAPT; aspirin plus P2Y12 inhibitor) strategy post-PCI, temporarily omitting OAC. The study aims to compare bleeding and ischaemic risk between a 30-day DAPT strategy following PCI and a guideline-directed therapy in AF patients requiring OAC. WOEST-3 (ClinicalTrials.gov: NCT04436978) is an investigator-initiated, international, open-label, randomised controlled trial (RCT). AF patients requiring OAC who have undergone successful PCI will be randomised within 72 hours after PCI to guideline-directed therapy (edoxaban plus P2Y12 inhibitor plus limited duration of aspirin) or a 30-day DAPT strategy (P2Y12 inhibitor plus aspirin, immediately discontinuing OAC) followed by DAT (edoxaban plus P2Y12 inhibitor). With a sample size of 2,000 patients, this trial is powered to assess both superiority for major or clinically relevant non-major bleeding and non-inferiority for a composite of all-cause death, myocardial infarction, stroke, systemic embolism or stent thrombosis. In summary, the WOEST-3 trial is the first RCT temporarily omitting OAC in AF patients, comparing a 30-day DAPT strategy with guideline-directed therapy post-PCI to reduce bleeding events without hampering efficacy.